Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 16/20 | 0.65 |
| ▸ | MMP3 | P08254 | 16/20 | 0.65 |
| ▸ | MMP7 | P09237 | 14/20 | 0.65 |
| ▸ | MMP1 | P03956 | 15/20 | 0.64 |
| ▸ | MMP8 | P22894 | 2/20 | 0.64 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.64 |
| ▸ | MMP9 | P14780 | 1/20 | 0.64 |
| ▸ | MMP12 | P39900 | 1/20 | 0.64 |
| ▸ | MMP13 | P45452 | 1/20 | 0.64 |
| ▸ | MMP14 | P50281 | 1/20 | 0.64 |
| ▸ | FCER2 | P06734 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4431907 | 0.92 | MMP2 (0.78) | MMP2MMP3MMP7MMP1MMP8 | |
| SCHEMBL4425335 | 0.92 | MMP2 (0.78) | MMP2MMP3MMP7MMP1MMP8 | |
| SCHEMBL6803244 | 0.92 | MMP2 (0.67) | MMP2MMP3MMP7MMP1MMP8 | |
| SCHEMBL7651203 | 0.92 | MMP2 (0.67) | MMP2MMP3MMP7MMP1MMP8 | |
| SCHEMBL7651206 | 0.92 | MMP2 (0.67) | MMP2MMP3MMP7MMP1MMP8 | |
| SCHEMBL6804731 | 0.90 | MMP2 (0.66) | MMP2MMP3MMP7MMP1MMP8 | |
| SCHEMBL6804212 | 0.89 | MMP2 (0.60) | MMP2MMP3MMP7MMP1MMP8 | |
| SCHEMBL7376771 | 0.89 | MMP2 (0.72) | MMP2MMP3MMP7MMP1MMP8 | |
| SCHEMBL6801553 | 0.88 | MMP3 (0.63) | MMP2MMP3MMP7MMP1MMP8 | |
| SCHEMBL6801588 | 0.87 | MMP2 (0.62) | MMP2MMP3MMP7MMP1MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104955332-A | Method for controlling arthropod pest | SUMITOMO CHEMICAL CO | 2015-09-30 | — | — | CN | disclosed |
| CN-104105694-A | Amide compound and use thereof for pest control | SUMITOMO CHEMICAL CO | 2014-10-15 | — | — | CN | disclosed |
| US-6790834-B1 | Cytostatic agents | BRITISH BIOTECH PHARMACEUTICALS, LTD. (GB) | 2004-09-14 | — | — | US | disclosed |
| US-20040110665-A1 | Desleucyl glycopeptide antibiotics and methods of making same | KAHNE DANIEL (US) | 2004-06-10 | — | — | US | disclosed |
| EP-1062202-B1 | CYTOSTATIC AGENTS | BRITISH BIOTECH PHARM (GB) | 2003-01-15 | — | — | EP | disclosed |
| US-6462023-B1 | SUCH AS 2-HYDROXY-HYDROXYCARBAMOYL-METHYL)-4-METHYL-PENTANOYLAMINE)-2-PHENYL -ETHANOIC ACID CYCLOPENTYL ESTER; INHIBITING HYPERPROLIFERATIVE TUMOURGENIC CELLS SUCH AS MELANOMA AND/OR LYMPHOMA CELLS | BRITISH BIOTECH PHARMACEUTICALS, LTD. (GB) | 2002-10-08 | — | — | US | disclosed |
| EP-0925278-B1 | CYTOSTATIC HYDROXAMIC ACID DERIVATIVES | BRITISH BIOTECH PHARM (GB) | 2002-07-17 | — | — | EP | disclosed |
| CN-1071334-C | Glycopeptide antibiotic derivatives | LILLY CO ELI (US) | 2001-09-19 | — | — | CN | disclosed |
| US-6169075-B1 | ANTITUMOR AGENT INHIBITING THE PROLIFERATION OF A RANGE OF RAPIDLY DIVIDING TUMOUR CELLS LIKE MELANOMA AND/OR LYMPHOMA CELLS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2001-01-02 | — | — | US | disclosed |
| EP-1062202-A1 | CYTOSTATIC AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-12-27 | — | — | EP | disclosed |
| WO-1999046241-A1 | CYTOSTATIC AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-09-16 | — | — | WO | disclosed |
| EP-0925278-A1 | CYTOSTATIC HYDROXAMIC ACID DERIVATIVES | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-06-30 | — | — | EP | disclosed |
| WO-1998011063-A1 | CYTOSTATIC HYDROXAMIC ACID DERIVATIVES | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1998-03-19 | — | — | WO | disclosed |
| CN-1119649-A | Glycopeptide antibiotic derivatives | LILLY CO ELI (US) | 1996-04-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110665-A1 | Desleucyl glycopeptide antibiotics and methods of making same | FUT6, FUT5, ST6GAL1 | MMP2 1331/4885MMP3 2460/4885MMP7 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.